ClinicalTrials.gg
CompletedNCT02397382Updated Sep 20, 2017

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

A Phase 1 interventional study of Guselkumab and Midazolam in Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 8 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-09-20.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.

Enrollment
25th of 29
16 · median 120
Started
2015
with 2 others
Phase 1
2 of 29
none open now
Registered
7th of 29
by date
Lead sponsor
9 of 29
Janssen Research & Development, LLC

Among the 29 studies testing guselkumab in Psoriasis, this one is the 25th largest by enrollment, is one of 3 that started in 2015, is one of 2 in phase 1, and was the 7th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing guselkumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the potential effects of a single dose of 200 milligram (mg) guselkumab on the plasma concentrations of a cocktail of representative probe substrates of Cytochrome P450 isozymes (CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2) in participants with moderate to severe psoriasis.

Read the detailed description

This is an open-label, multi-center study. The total duration of study will be approximately 17 weeks per participant, including Screening phase (up to 4 weeks prior to first probe cocktail administration). Participants will have 4 in-patient periods on Day 1, 8, 15 and 36 (3 periods consisting of 3 days and 2 nights each and 1 consisting of 2 days and 1 night) followed by follow up period (up to Day 92). All Participants will receive a single 200 mg subcutaneous (SC) injection (2*100 mg) of guselkumab on Day 8 and probe cocktail on Days 1, 15 and 36. Blood samples will be collected for the evaluation of pharmacokinetics and immunogenicity at pre-dose and post-dose of study treatment. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • Guselkumab
  • Cytochromes P450
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of plaque-type psoriasis with or without psoriatic arthritis (PsA) for at least 6 months before Day 1
  • Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at Screening
  • Have an Investigator's Global Assessment (IGA) >= 3 at Screening
  • Have an involved body surface area (BSA) >= 10 percent (%) at Screening
  • Be a candidate for phototherapy or systemic treatment for psoriasis

Exclusion criteria

Exclusion Criteria:

  • Has a history of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac (including unstable cardiovascular disease, defined as a recent clinical deterioration (example, unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months), vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, bleeding disorder, rheumatologic, psychiatric, or metabolic disturbances
  • Have a pulse oximetry value less than (\<) 94 % at Screening
  • Genetically determined poor metabolizers of CYP2C9, CYP2C19, and CYP2D6 substrates
  • Is currently undergoing or has previously undergone allergy immunotherapy for a history of anaphylactic reactions
  • Has a transplanted organ (with exception of a corneal transplant greater than (>) 3 months before Day 1)
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Guselkumab and Cytochrome P450 Probe Cocktail

    Participants will be administered single dose of Guselkumab 200 milligram (mg) by subcutaneous injection (2\*100 mg) on Day 8 and Cytochrome P450 probe cocktail consist of midazolam, warfarin/vitamin K, omeprazole, dextromethorphan and caffeine orally once on Day 1,15 and 36.

    Drug: Guselkumab · Drug: Midazolam · Drug: Warfarin · Drug: Omeprazole · Drug: Dextromethorphan · Drug: Caffeine

Interventions

  • Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2\*100 mg) on Day 8.

  • DrugMidazolam

    Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.

  • DrugWarfarin

    Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.

  • DrugOmeprazole

    Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.

  • DrugDextromethorphan

    Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.

  • DrugCaffeine

    Caffeine will be administered orally as probe cocktail containing 100 mg once on Day 1, 15 and 36.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    The Cmax is the maximum observed plasma concentration of Midazolam, Omeprazole, Dextromethorphan, Caffeine and S-warfarin.

    Time frame: Screening up to 96 hours on Day 1, 15 and 36

  2. Time to Reach Maximum Concentration (Tmax)

    The Tmax is time to reach the maximum observed plasma concentration of Midazolam, Omeprazole, Dextromethorphan, Caffeine and S-warfarin.

    Time frame: Screening up to 96 hours on Day 1, 15 and 36

  3. Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])

    The AUC (0-last) is area under the plasma concentration-time curve from time zero to time of last quantifiable concentration of Midazolam, Omeprazole, Dextromethorphan, Caffeine and S-warfarin.

    Time frame: Screening up to 96 hours on Day 1, 15 and 36

  4. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - infinity])

    The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to extrapolated infinite time.

    Time frame: Screening up to 96 hours on Day 1, 15 and 36

  5. Serum Concentration of Guselkumab

    The observed serum concentration of Guselkumab.

    Time frame: Pre-dose on Day 8 and up to Day 92

  6. Number of Participants with antibody to CNTO1959

    The frequency of anti-CNTO1959 antibodies.

    Time frame: Pre-dose on Day 8 and up to Day 92

Secondary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    The incidence of TEAEs and SAEs from the screening visit and until the follow-up contact will be will be summarized by treatment period.

    Time frame: Up to 92 Days

07

Study locations

8 sites
  • Anniston, Alabama, United States
  • North Hollywood, California, United States
  • Orlando, Florida, United States
  • Atlanta, Georgia, United States
  • High Point, North Carolina, United States
  • Duncansville, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • San Antonio, Texas, United States
08

References and documents

Publications

  • Zhu Y, Xu Y, Zhuang Y, Piantone A, Shu C, Chen D, Zhou H, Xu Z, Sharma A. Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab. Clin Transl Sci. 2020 Nov;13(6):1217-1226. doi: 10.1111/cts.12807. Epub 2020 May 28. PubMed 32407591 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Aug 2016, 14 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 14 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2015
First posted
Mar 25, 2015
StartActual
Jun 18, 2015
Primary completionActual
Aug 31, 2016
CompletionActual
Aug 31, 2016
Last update
Sep 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02397382
Responsible party
Sponsor
First posted
Mar 25, 2015
Start date
Jun 18, 2015
Primary completion
Aug 31, 2016
Completion
Aug 31, 2016
Last update
Sep 20, 2017

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion